🚨Trade Alert 🚨 BNOX

Underfollowed biotech company BNOX may flourish in the anticipated biotech rebound of 2024!  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Underfollowed biotech company BNOX may flourish in the anticipated biotech rebound of 2024! Greetings Investors, 2024 may be the year that the winds finally shift for biotech stocks after several rough years. With big declines in 2021 and 2022, the SPDR S&P Biotech exchange-traded fund XBI was up a little in 2023 but still lagged behind the SPX. With the Federal Reserve lately taking a [more dovish stance]( investors’ risk appetite should rise, and “the pendulum could swing back to biotech,” analysts at Leerink Partners wrote in a report recently. According to analysts, a more favorable interest rate outlook and an uptick in deals and innovations are setting up the biotech industry for a rebound. Some significant deals have been completed in recent months despite regulatory scrutiny. Only weeks ago, Bristol Myers Squibb Co. announced [a massive $14 billion deal]( buy Karuna Therapeutics Inc., which has a key schizophrenia treatment in development. With that said, one quietly trading NASDAQ biotech company could be ripe for major upward movement this year given the exciting data it announced not long ago. And its lead candidate looks to be getting closer to the possibility of FDA approval and commercialization! The company is called Bionomics Limited (NASDAQ: BNOX) and trades at a little over $1 a share. BNOX is a clinical-stage biotechnology company is developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical needs. [www.bionomics.com.au]( [AmericanBulls.com]( has a “STAY LONG” rating on the stock while [NASDAQ.com]( shows a “STRONG BUY” rating and a $8 price target! This past fall shares of BNOX had soared over 400% on positive data results. Could a move like this be on the horizon again? Wall Street seems to be reacting optimistically to the company’s recent positive updates on the company’s PTSD (Post Traumatic Stress Disorder) and SAD (Social Anxiety Disorder) Candidate – BNC210. About Social Anxiety Disorder: SAD is a significant and persistent fear of social and performance-related situations. One of the most common mental disorders in the United States, an estimated 31 million Americans will suffer from SAD at some point in their lives. SAD can interfere with a person’s ability to work, make it difficult to maintain friendships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging. Fifteen million, or seven percent, of American adults have Social Anxiety Disorder. More than 75% of people experience their first symptoms during their childhood or early teenage years. People with social anxiety disorder are also at an increased risk for substance use disorder and major depressive disorder. [(SOURCE)]( About PTSD: Post-traumatic stress disorder (PTSD) is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. It is natural to feel afraid during and after a traumatic situation. Fear triggers many split-second changes in the body to help defend against danger or to avoid it. About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any given year. In 2020, about 13 million Americans had PTSD. Women are more likely to develop PTSD than men. About 8 of every 100 women (or 8%) and 4 of every 100 men (or 4%) will have PTSD at some point in their life. ([SOURCE]( What is BNC210? BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of SAD and PTSD. Utilizing the company’s deep expertise in ion channel biology and translational medicine, it designs best-in-class oral, small molecules to modulate ion channel function, influence neurotransmission and consequently downstream signaling in the brain. The company is currently focused on its proprietary allosteric modulators. Negative allosteric modulators (“NAMs”) of the α7 receptor are developed for the treatment of anxiety and stressor-related disorders and Positive allosteric modulators (“PAMs”) are developed for the treatment of cognitive dysfunction. Fast Track Designation… The FDA had already granted a Fast Track designation to BNC210, a designation that provides the company with additional market exclusivity and expedited regulatory paths. Fast track designation is designed to aid in the development and expedite the review of drugs that show promise in treating a serious or life-threatening disease and address an unmet medical need. Several positive updates… In December BNOX announced the presentation of data on the psychometric validity and reliability of SUDS as an outcome measure in assessing anxiety in SAD clinical trials at the 2023 American College of Neuropsychopharmacology Annual Meeting taking place December 3 – 6 in Tampa, Florida. “We are excited to share the psychometric analysis we conducted of SUDS utilization in the Phase 2 PREVAIL trial of BNC210 in SAD, demonstrating it is a valid, reliable, and sensitive tool to assess anxiety,” commented Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “This presentation follows up the successful End-of-Phase 2 meeting we recently had with the U.S. Food and Drug Administration (FDA) where we agreed on the plan for our registrational study of BNC210 in SAD, including the measurement of SUDS during a public speaking challenge as the primary efficacy endpoint.” SUDS will be used to assess the effect of BNC210 on reduction in anxiety during a public speaking challenge in the upcoming Phase 3 trial, which is anticipated to begin in Q1’24. The company had successful and favorable outcomes of an End-of-Phase 2 meeting (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its lead asset BNC210 for the acute treatment of Social Anxiety Disorder (SAD) into Phase 3 registrational studies based on the recently completed Phase 2 PREVAIL dataset. - Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety Disorder. - Company confirms agreement with the FDA on Phase 3 clinical program and alignment on nonclinical toxicology studies required for registration. - Company is on track for first patient dosed in the Phase 3 program planed for Q1’24. And topline data from the Phase IIb ATTUNE trial showed that [Bionomics]( investigational ion channel modulator BNC210 [met the study’s primary endpoint]( significantly reducing symptoms in patients with post-traumatic stress disorder. After 12 weeks of treatment, patients who were given BNC210 saw strong improvements in PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The effect was statistically significant, according to the company’s announcement. Significant improvements in CAPS-5 scores were apparent as early as week four and were maintained through week eight. The results from ATTUNE could “enable FDA discussions for the registrational path of BNC210 in PTSD,” according to Bionomics CEO Spyros Papapetropoulos. These data also position the candidate “as a compelling late-stage experimental therapeutic for multiple prevalent neuropsychiatric diseases with high unmet need,” Papapetropoulos said in a statement. The primary endpoint of the study is to evaluate the change in symptom severity score measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) compared to placebo. Other Company Highlights… Beyond BNC210, BNOX has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. In Summary… These are exciting times for BNOX and the company’s news should be watched closely. The successful development and commercialization of BNC210 could boost BNOX’s prospects significantly! “We continue our strong momentum with our fast track designated BNC210, with a robust clinical and regulatory milestone-rich year in both SAD and PTSD, two highly prevalent neuropsychiatric disorders with significant unmet needs,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. BNOX may still be at a supreme value right now and with strategic moves from management, a promising pipeline, and potential FDA news soon, now is the time to have the company on your radar! The FDA has granted a Fast Track designation to BNC210 for treatment of patients with PTSD and SAD. The designation provides the company with additional market exclusivity and expedited regulatory paths. This pull back for BNOX could mean a big opportunity. Shares are no stranger to tremendous breakouts, given the massive 400%+ rally this past fall. With a hefty price target of $8 on the stock and a “STRONG BUY” rating as well as any potential positive developments to come, all could serve as catalysts for another big rally for BNOX! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BNOX. We have been currently compensated up to Five Thousand Dollars Cash ($5,000) via bank wire transfer from a third-party Interactive Offers, LLC for a 1 Day Marketing Program regarding BNOX with a start date of 1/04/2024. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2024 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]